Boehringer Ingelheim: Digital DevOps for Cell Culture | Joachim Bär | AUTOMA+ 2025

Описание: Joachim Bär, Director DevOps for Cell Culture at Boehringer Ingelheim Pharma GmbH & Co KG, represents one of Germany’s leading family-owned pharmaceutical companies, active in human prescription medicines, animal health and biotech manufacturing services. He highlights the creative, open culture that supports innovation across complex pharmaceutical operations.

At AUTOMA+ 2025, Joachim shared practical insights into digital implementation in regulated environments, stressing that successful transformation depends on choosing the right timing, decision-makers and use cases. He underlined that digital progress is rarely linear and often challenging, but ultimately rewarding when organisations are willing to navigate complexity. A key takeaway was the importance of breaking silos between people rather than focusing solely on data, ensuring shared understanding across scientific, regulatory and digital teams.

Joachim also reflected on the value of AI in harmonising documentation across systems, improving alignment for regulatory submissions. He praised AUTOMA+ for exposing him to new perspectives beyond his usual focus, particularly regulatory discussions, and for the strong networking format supported by BGS Group, which made meaningful connections easy and impactful.

📍 Filmed at AUTOMA+ 2025 – Pharma Automation & Digitalisation Congress
🎥 Organised by BGS Group – https://bgs.group/events/

🔗 Learn more about AUTOMA+: https://automa.plus/

🔗 Follow BGS Group for more insights from pharma and digital leaders –    / @bgsgroup  

#AUTOMAplus2024 #BoehringerIngelheim #PharmaDigitalisation #DevOps #CellCulture #AIinPharma #ChangeManagement #Regulatory #LifeSciences #BGSGroup

00:00 Introduction
00:21 Company overview and pharma portfolio
01:17 Digital implementation challenges and decision-making
02:24 Regulatory insights and new perspectives
03:26 Breaking silos between people, not just data
04:14 AI for document alignment and regulatory confidence
05:23 Networking experience and value of AUTOMA+